Next Article in Journal
Phylogenetic Analysis of the Synnema-Producing Genus Synnemapestaloides
Next Article in Special Issue
Special Issue “Aspergillus fumigatus: From Diagnosis to Therapy”
Previous Article in Journal
New Horizons in Antifungal Therapy
Previous Article in Special Issue
Treatment of Primary Pulmonary Aspergillosis: An Assessment of the Evidence
Correction of J. Fungi 2016, 2(3), 25.
Open AccessCorrection

Correction: Stewart, E.R.; Thompson, G.R. Treatment of Primary Pulmonary Aspergillosis: An Assessment of the Evidence. J. Fungi 2016, 2, 25.

1
Department of Internal Medicine, Division of Infectious Diseases, Davis Medical Center, 4150 V Street, Suite G500, Sacramento, CA 95817, USA
2
Department of Medical Microbiology and Immunology, University of California, Rm. 3138, Tupper Hall, One Shields Ave, Davis, CA 95616, USA
*
Author to whom correspondence should be addressed.
Academic Editor: William J. Steinbach
J. Fungi 2016, 2(4), 27; https://doi.org/10.3390/jof2040027
Received: 3 November 2016 / Revised: 4 November 2016 / Accepted: 4 November 2016 / Published: 4 November 2016
(This article belongs to the Special Issue Aspergillus fumigatus: From Diagnosis to Therapy)
The authors of the published paper [1] would like to correct Table 1. The sixth row in the second column should have been Amphotericin B Lipid Complex (ABLC). Therefore, Table 1 should read as follows:
We apologize for any inconvenience caused to readers. The manuscript will be updated and the original will remain available on the article webpage.

Conflicts of Interest

The authors declare no conflict of interest.

Reference

  1. Stewart, E.R.; Thompson, G.R. Treatment of Primary Pulmonary Aspergillosis: An Assessment of the Evidence. J. Fungi 2016, 2, 25. [Google Scholar] [CrossRef]
Table 1. Treatment recommendations for invasive aspergillosis.
Table 1. Treatment recommendations for invasive aspergillosis.
RecommendationDrugDosingComments
PrimaryVoriconazole6 mg/kg IV every 12 h times two then 4 mg/kg IV every 12 hOral therapy at mg/kg dosing or 200–300 mg every 12 h; TDM required
AlternativesLipsosomal amphotericin B (L-AMB)3–5 mg/kg/day IV
Isavuconazole200 mg every 8 h IV or PO times six then 200 mg daily IV or PONeed for TDM remains undefined
Voriconazole plus AnidulafunginVorizonazole as above plus Anidulafungin 200 mg IV daily times one then 100 mg IV dailyCombination therapy considered in severe disease and with hematologic malignancy
Amphotericin B Lipid Complex (ABLC)5 mg/kg/day IV
SecondaryCaspofungin70 mg IV daily times one then 50 mg IV dailyMonotherapy as salvage
PosaconazoleOral suspension: 200 mg PO every 8 h, Tablet: 300 mg PO every 12 h times two then 300 mg PO daily, Intravenous: 300 mg IV every 12 h times two then 300 mg IV dailyCaution in use of tablet formulation with acid suppression; TDM required
Itraconazole200 mg PO every 12 hTDM required
Back to TopTop